MBF Therapeutics Inc. is a biotechnology startup that focuses on developing next-generation immunotherapeutics for the life sciences industry. The company's innovative T-Max™ immunotherapeutic DNA vaccine platform is primarily targeted at animal applications, with potential opportunities in human health as well. The T-Max platform addresses shortcomings of traditional viral vaccine technologies, aiming to create safe and efficacious vaccines for respiratory viral diseases with significant economic and social impacts.
The company's T-Max™ DNA vaccine platform sets itself apart through several key components, including a novel antigen selection process, cloning into proprietary plasmids, incorporation of immunomodulators, and CaptaVa. These elements work together to stimulate durable and potent T cell immune responses, with the potential to create cross-protective "universal" vaccines.
Founded in 2008, MBF Therapeutics operates within the biotechnology, health and wellness, and life sciences industries. The company recently received a $256.00K grant investment on 21 December 2021 from the National Science Foundation.
